The Urine Revolution: Craif's AI Test Aims to Conquer Early Cancer Diagnosis

SAN DIEGO, CA – August 18, 2026 – In the relentless battle against cancer, the most powerful weapon remains early detection. Yet, our most effective screening tools are often invasive, expensive, or simply don't exist for some of the deadliest forms of the disease. A Japanese bio-AI company, Craif Inc., is poised to challenge that reality, and it just secured a significant war chest to bring the fight to American soil.

Craif today announced the close of an approximately $33 million Series D funding round, bringing its total capital raised to a formidable $88 million. The infusion of capital, co-led by Granite-Integral and Japanese diagnostics giant Tauns Co., Ltd., is earmarked for a strategic and ambitious push into the United States—the world's largest and most complex healthcare market. The goal: to introduce a non-invasive, urine-based test that uses artificial intelligence to flag the faint, early signals of cancer.

A New Frontier in Diagnostics

At the heart of Craif's platform is a technology that feels like it's pulled from the pages of science fiction, yet is grounded in Nobel Prize-winning science. The company focuses on microRNAs (miRNAs), tiny molecules that regulate gene expression. The discovery of these molecules, recognized by the 2024 Nobel Prize in Physiology or Medicine, revealed a new layer of our biological code. Crucially, their dysregulation is a known hallmark of cancer's onset and progression.

While these biological tell-tales are present in bodily fluids, they are notoriously fragile and exist in trace amounts, making them difficult to analyze. This is where Craif's proprietary NANO IP® (NANO Intelligence Platform) comes in. The system efficiently isolates miRNAs from a simple urine sample, protecting them for analysis. Then, the company's “Bio-AI” takes over, using machine learning algorithms trained on one of the world's largest urine datasets to identify patterns indicative of disease. This platform can currently screen for 10 different cancers, including lung, breast, and colorectal.

The approach represents a significant departure from the current landscape. While blood-based “liquid biopsies” are gaining traction, Craif is betting on the simplicity and accessibility of urine. A test that requires no needles and can be collected with minimal fuss has the potential to dramatically lower the barrier to screening, encouraging participation from patients who might otherwise avoid or delay testing.

A New Hope for Pancreatic Cancer

Nowhere is the need for a new approach more acute than in pancreatic cancer. With a five-year survival rate of just 13%, it remains one of the most lethal cancers, largely because it is almost always found too late. An estimated 80% of patients are diagnosed at an advanced stage when treatment options are limited and prognoses are bleak. There is no routine screening test for the general population.

This is the challenge Craif is tackling head-on. The company's immediate focus for the U.S. market is a test for pancreatic cancer, an indication where, as the company notes, “the clinical utility and the path to reimbursement are clear.” The promise is not necessarily to replace definitive imaging like CT or MRI scans, but to provide a crucial first step. As outlined in their plans, “A simple, non-invasive urine test could help clinicians decide who needs further workup and who can safely wait.”

This isn't just a theoretical goal. Craif has already published peer-reviewed research demonstrating its AI algorithm can detect early-stage (Stage I/IIA) pancreatic cancer with 93% sensitivity and 93% specificity. For a disease defined by its stealth, a tool that can reliably shine a light on it this early would be nothing short of revolutionary, shifting the paradigm from late-stage treatment to proactive intervention.

The Trans-Pacific Gambit

Craif’s U.S. expansion is not a leap of faith; it’s a calculated scale-up built on a foundation of proven success. In its native Japan, the company’s flagship test, miSignal, is already a fixture in the healthcare system, available in over 2,500 medical institutions and 4,500 pharmacies, with more than 110,000 tests performed to date.

To replicate this success, Craif is methodically building a U.S. operation from the ground up. The company established a subsidiary in 2022, joined the prestigious JLABS incubator, and in April of this year, opened a state-of-the-art bio-AI laboratory in the biotech hub of San Diego. In a clear signal of intent, CEO and co-founder Ryuichi Onose has relocated to lead the U.S. business himself.

“I moved to San Diego to build our U.S. business myself, because the United States is the hardest and most important market to prove this technology,” Onose stated.

Key to navigating this difficult market is leadership. Craif recently appointed Dr. Nicholas Bevins as Chief Medical Officer. A board-certified clinical pathologist with a rare combination of scientific, medical, and regulatory expertise, Dr. Bevins has served as a CLIA laboratory director—a critical qualification for offering laboratory-developed tests in the U.S. His role will be to steer the company through the intricate web of clinical trials and regulatory requirements needed to secure reimbursement and physician adoption.

“I joined Craif because the company has built a differentiated platform, generated an extraordinary body of clinical evidence in Japan, and is committed to advancing science through rigorous data rather than hype,” Dr. Bevins said.

The Power of Strategic Capital

The investor roster for this funding round speaks volumes about Craif's strategy. The co-leads are not typical venture capitalists. Granite-Integral is a joint venture specifically created to bridge Japanese innovation with global markets. Tauns Co., Ltd. is one of Japan's largest makers of rapid diagnostic tests and, critically, is already a distribution partner for miSignal.

This is smart money in its purest form—investors who not only provide capital but also possess deep domain expertise and vested strategic interests in Craif’s success. “Cancer screening should be as simple as a routine check-up, not a procedure patients avoid,” said CK Chuon, Partner & Co-Head at Granite-Integral. “Craif has proven in Japan that a non-invasive urine test can detect cancer early and at scale, and we believe the same approach can unlock massive unmet demand in the United States.”

Masataka Nonaka, President of Tauns, echoed this sentiment, noting the funding would accelerate Craif's global expansion and move its programs “closer to real-world clinical use.” The partnership underscores a shared vision to transform diagnostics on a global scale.

With a proven product, a clear strategic focus, and powerful financial and operational backing, Craif is embarking on a mission that could redefine our relationship with one of humanity's most feared diseases. As CEO Ryuichi Onose noted, the ambition extends far beyond a single test. “The earliest signals of many diseases show up in urine, and reading them is what Craif is really about. Cancer is the first step.”